Fatal Tumor Lysis Syndrome Following Sorafenib Treatment

Abstract

Sorafenib is one of the few approved treatments for advanced hepatocellar carcinoma. It is an oral multi-targeted tyrosine kinase inhibitor. It could be associated with a wide variety of adverse effects. However tumor lysis syndrome was reported in 2 cases only following sorafenib treatment. Here we report a fatal case of tumor lysis syndrome 3 weeks following sorafenib treatment in a patient with advanced hepatitis B virus-related hepatocellular carcinoma. We suggest using preventing measures for TLS prior to initiation of such treatment.




J Med Cases. 2013;4(4):269-270
doi: https://doi.org/10.4021/jmc1049w